WebTell your doctor right away if you are unable to empty your bladder. The most common side effects of GEMTESA include headache, urinary tract infection, nasal congestion, sore throat or runny nose, diarrhea, nausea and upper respiratory tract infection. These are not all the possible side effects of GEMTESA. For more information, ask your doctor ... WebDiscontinue GEMTESA in patients who develop urinary retention. ADVERSE REACTIONS. Most common adverse reactions (≥ 2%) reported with GEMTESA were headache, urinary tract infection, nasopharyngitis, diarrhea, nausea, and upper respiratory tract infection. Please see full Prescribing Information.

Staying on Track GEMTESA® Resources

WebMore than 500 patients were studied in the 40-week extension period 1 Study design description. A 12-week, phase 3, randomized, double-blind, placebo- and active … WebGemtesa (251 reports) Renografin-76 ; How the study uses the data? The study uses data from the FDA. It is based on vibegron and diatrizoate meglumine; diatrizoate sodium (the active ingredients of Gemtesa and Renografin-76, respectively), and Gemtesa and Renografin-76 (the brand names). Other drugs that have the same active ingredients (e.g ... japan chronicle

GEMTESA® Patient Access & Support Resources

WebGemtesa (251 reports) How the study uses the data? The study uses data from the FDA. It is based on cupric sulfate; manganese sulfate; selenious acid; zinc sulfate and vibegron (the active ingredients of Tralement and Gemtesa, respectively), and Tralement and Gemtesa (the brand names). Other drugs that have the same active ingredients (e.g ... WebJan 11, 2024 · The FDA approved GEMTESA based on evidence from one clinical trial (Trial 1/ NCT03492281) of 1085 adult patients 18 to 93 years old with OAB. The trial was … WebIMPORTANT SAFETY INFORMATION. CONTRAINDICATIONS. GEMTESA is contraindicated in patients with known hypersensitivity to vibegron or any components of the product. WARNINGS AND … lowe\u0027s 0 interest for 18 months